Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT: Eculizumab for DGF Prevention
NCT02145182Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Aug 2014
- Primary completion
- Nov 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of eculizumab in delayed graft function (DGF), sponsored by Alexion Pharmaceuticals. Started Aug 2014; status: completed.
02
Drugs
eculizumab
03
Conditions
delayed graft function (DGF)
Beyond the preview
Go deeper on NCT02145182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02145182.